Published December 15, 2022 | Version v1
Project deliverable Open

FAIRplus use case IMI CARE: Quick-response COVID-19 effort opens FAIR data on ~5,500 compounds

  • 1. Lygature
  • 2. University of Manchester
  • 3. Fraunhofer Institute for Molecular Biology and Applied Ecology IME


The IMI CARE project was initiated in response to the COVID-19 pandemic with the goal to deliver treatments for COVID-19 and future coronavirus outbreaks. Started in April 2020, CARE not only focuses on delivering novel drugs designed specifically to treat COVID-19 and other coronaviruses, but also on ‘repurposing’ approved drugs and drug candidates that were originally developed for other diseases that could potentially treat COVID-19. By making CARE data public, it also helps other drug repurposing studies. The CARE project is sharing its scientific results through open-access platforms and peer-reviewed journals, as well as via relevant conferences and other events.

Recently, in the context of the CARE project, Janssen Pharmaceutica published a dataset in the public domain describing the results of ~5,500 FDA-approved drugs and clinical candidates that have passed Phase I studies which were screened for anti-SARS-CoV-2 activity. The FAIRplus squad team supported the Janssen Pharmaceutica coronavirus discovery team to improve findability, interoperability, and reuse of the drug data.



Files (2.9 MB)

Name Size Download all
2.9 MB Preview Download

Additional details


FAIRplus – FAIRplus 802750
European Commission